The efficacy of conditioned medium released by tonsil-derived mesenchymal stem cells in a chronic murine colitis model

Lee, Ko Eun; Jung, Sung Ae; Joo, Yang Hee; Song, Eun Mi; Moon, Chang Mo; Kim, Seong Eun; Jo, Inho

doi:10.1371/journal.pone.0225739

Cited by 14 publications

(14 citation statements)

References 41 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, to date, the effect of T-MSCs-CM has not been investigated thoroughly compared to that of T-MSCs themselves. A prior study for chronic colitis model showed that T-MSCs-CM-treated group has an equivalent effect to T-MSCs-treated group regarding the immunomodulatory effect [27]. Consistent with this, the addition of T-MSCs-CM on the AR mouse model showed a similar immunomodulatory effect, compared with the previous study regarding T-MSCs on the AR mouse model.…”

Section: Discussionsupporting

confidence: 72%

The Supernatant of Tonsil-Derived Mesenchymal Stem Cell Has Antiallergic Effects in Allergic Rhinitis Mouse Model

Park

Kim

Bae

et al. 2020

Mediators of Inflammation

View full text Add to dashboard Cite

Background and Purpose. Recently, tonsil-derived mesenchymal stem cells (T-MSCs) have attracted great attention in various medical fields due to easier harvest of T-MSCs and more immunomodulatory effects than adipose-derived MSCs. However, there was still little evidence of the effect of conditioned media from T-MSCs (T-MSCs-CM) on allergic rhinitis (AR). Therefore, we investigated the impact of T-MSCs-CM on an AR mouse model. Methods. We isolated T-MSCs from human palatine tonsil and evaluated the ingredients of T-MSCs-CM. The effect of T-MSCs-CM was evaluated in the AR mouse model that was randomly divided into five groups (negative control, positive control, and T-MSCs-CM treated (0.1 mg, 1 mg, and 10 mg)). To investigate the therapeutic effect, we analyzed rhinitis symptoms, serum immunoglobulin (Ig), inflammatory cells, and cytokine expression. We also assessed T cell receptor signal, including MAP kinase (ERK/JNK), p65, and NFAT1. Results. We identified the increment of TGF-β1, PGE2, and HGF in the T-MSCs-CM. In an animal study, the T-MSCs-CM-treated group showed significantly reduced allergic symptoms and infiltration of eosinophils and neutrophils in the nasal mucosa, whereas there was no significant difference in total IgE and the OVA-specific IgE level. Additionally, we found that the 10 mg T-MSCs-CM-treated group showed a significantly decreased IL-4 mRNA expression, compared to the (+) Con group. In the analysis of T cell receptor signal, the phosphorylation of MAP kinases, translocation of p65, and activation of NFAT1 were inhibited after T-MSCs-CM. Conclusions. Our findings suggest that T-MSCs-CM showed a partial immunomodulatory effect on the AR mouse model by the inhibition of T cell activation via MAP kinase, p65, and NFAT1.

show abstract

Section: Discussionsupporting

confidence: 72%

The Supernatant of Tonsil-Derived Mesenchymal Stem Cell Has Antiallergic Effects in Allergic Rhinitis Mouse Model

Park

Kim

Bae

et al. 2020

Mediators of Inflammation

View full text Add to dashboard Cite

show abstract

“…can affect the final outcome of the treatment of UC [37]. MSCs could be easily isolated and are amplified from several tissues for the treatment of UC, including bone marrow-derived stem cells (BMSCs) [38], adipose tissue-derived stem cells (adSCs) [29], umbilical cord stem cells (UCSCs) [39], endometrial regenerative cells (EndSCs) [40], placenta [41], intestinal stem cells (ISCs) [42], amnion [43], amniotic fluid [44], and tonsil [45]. Their routes of administration were reported to be intraperitoneal (IP), intravenous (IV), subcutaneous (SC), endoscopic, systemic, or anal injection, which can affect the outcome of cell transplantation in UC [46][47][48].…”

Section: The Therapeutic Role Of Mscs In Ucmentioning

confidence: 99%

“…Tonsil-derived stem cells (TSCs) and CM derived from TSCs illustrated equivalent effects in the improvement of inflammation in a DSS-induced colitis mice model. After cell therapy, weight gain, recovery of colon length, reduction of disease activity index, and decrease in the expression level of the proinflammatory cytokines, interleukin (IL)-1β, IL-6, and IL-17, were visible [45] (Table 7). Table 7.…”

Section: In Vivo Studies On Treatment Of Uc Using Other Sources Of Mscsmentioning

confidence: 99%

Therapeutic Effect of Mesenchymal Stem Cells in Ulcerative Colitis: A Review on Achievements and Challenges

Hosseini-Asl

Mehrabani

Karimi‐Busheri

2020

JCM

View full text Add to dashboard Cite

The worldwide epidemiology of inflammatory bowel disease (IBD), including Crohn’s disease (CD) and ulcerative colitis (UC), still shows an increasing trend in Asia and Iran. Despite an improvement in the treatment landscape focused on symptomatic control, long-term colectomies have not decreased over the last 10-year period. Thus, novel therapies are urgently needed in clinics to supplement the existing treatments. Mesenchymal stem cells (MSCs) are multipotent adult stem cells with immunosuppressive effects, targeting IBD as a new treatment strategy. They have recently received global attention for their use in cell transplantation due to their easy expansion and wide range of activities to be engrafted, and because they are home to the mucosa of the intestine. Moreover, MSCs are able to differentiate into epithelial and other cells that can directly promote repair in the mucosal damages in UC. It seems that there is a need to deepen our understanding to target MSCs as a promising treatment option for UC patients who are refractory to conventional therapies. Here, we overviewed the therapeutic effects of MSCs in UC and discussed the achievements and challenges in the cell transplantation of UC.

show abstract

“…The higher convenience of obtaining adipose and umbilical cord MSCs has also increased their application across several studies [3,62]. Other sources of MSCs applied in IBD and colitis-associated CRC are amniotic fluid [63], placenta [64], tonsil [65], amnion [66,67], and endometrium regenerative cells [68], among others. The routes of administration are intraperitoneal, intravenous, and anal injection.…”

Section: Interaction Between Msc Ibd and Ibd-associated Crcmentioning

confidence: 99%

The Achievements and Challenges of Mesenchymal Stem Cell-Based Therapy in Inflammatory Bowel Disease and Its Associated Colorectal Cancer

Ocansey

Qiu

Wang

et al. 2020

Stem Cells International

View full text Add to dashboard Cite

Approximately 18.1×106 new cases of cancer were recorded globally in 2018, out of which 9.6 million died. It is known that people who have Inflammatory Bowel Disease (IBD) turn to be prone to increased risks of developing colorectal cancer (CRC), which has global incident and mortality rates of 10.2% and 9.2%, respectively. Over the years, conventional treatments of IBD and its associated CRC have been noted to provide scarce desired results and often with severe complications. The introduction of biological agents as a better therapeutic approach has witnessed a great deal of success in both experimental and clinical models. With regard to mesenchymal stem cell (MSC) therapy, the ability of these cells to actively proliferate, undergo plastic differentiation, trigger strong immune regulation, exhibit low immunogenicity, and express abundant trophic factors has ensured their success in regenerative medicine and immune intervention therapies. Notwithstanding, MSC-based therapy is still confronted with some challenges including the likelihood of promoting tumor growth and metastasis, and possible overestimated therapeutic potentials. We review the success story of MSC-based therapy in IBD and its associated CRC as documented in experimental models and clinical trials, examining some of the challenges encountered and possible ways forward to producing an optimum MSC therapeutic imparts.

show abstract

The efficacy of conditioned medium released by tonsil-derived mesenchymal stem cells in a chronic murine colitis model

Cited by 14 publications

References 41 publications

The Supernatant of Tonsil-Derived Mesenchymal Stem Cell Has Antiallergic Effects in Allergic Rhinitis Mouse Model

The Supernatant of Tonsil-Derived Mesenchymal Stem Cell Has Antiallergic Effects in Allergic Rhinitis Mouse Model

Therapeutic Effect of Mesenchymal Stem Cells in Ulcerative Colitis: A Review on Achievements and Challenges

The Achievements and Challenges of Mesenchymal Stem Cell-Based Therapy in Inflammatory Bowel Disease and Its Associated Colorectal Cancer

Contact Info

Product

Resources

About